Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
In the Journal of Medical Ethics, there is fascinating and fraught debate about the development and release of potential treatments for rapidly progressive, universally fatal, neurodegenerative diseases. The discussion focuses on the often antithetical views of a patient diagnosed with amyotrophic lateral sclerosis (ALS), his treating physicians, research neuroscientists and a medical ethicist.1 The debate centres on how best to promote drug discovery and the future release of potential treatments for patients struck down by this fatal condition, typically in the prime of their adult lives (figure 1).2 ,3 Despite acknowledgement of the various challenges regarding drug discovery, unfortunately no clear consensus about the best way forward appears to have been reached.
As noted by the patient with ALS, Les Halpin, the first author of the manuscript, sophisticated clinical trials have been conducted in ALS at least since the 1980s, yet riluzole remains the only moderately efficacious drug to have emerged as treatment for the disorder. There may be many reasons for trial failures,4 but one consequence has clearly been that pharmaceutical companies are now reluctant to invest in rare diseases such as ALS. In an attempt to reverse this trend, Halpin …
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.
- Research ethics
Read the full text or download the PDF:
Other content recommended for you
- Amyotrophic lateral sclerosis and the innate immune system: protocol for establishing a biobank and statistical analysis plan
- Amyotrophic lateral sclerosis and motor neuron syndromes in Asia
- Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial
- Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19
- Clinical trials in the ALS syndrome: it is time for change
- Sensitivity of brain MRI and neurological examination for detection of upper motor neurone degeneration in amyotrophic lateral sclerosis
- Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
- Stem cell renegades or pioneers?
- Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)
- Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues